Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic T regulatory cells (Stanford University)
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic T regulatory cells (Tregs) are an investigational adoptive cell therapy developed by Stanford University for the treatment of acute respiratory distress syndrome (ARDS) induced by COVID-19. Tregs are a specialized subpopulation of T cells that act to suppress immune responses, thereby maintaining homeostasis and self-tolerance. In the context of severe COVID-19, an overactive immune response can lead to a 'cytokine storm' and life-threatening lung injury. This therapy involves isolating Tregs from living related donors (either HLA-matched or haploidentical) via immunomagnetic selection from apheresis products. The cells are then infused intravenously into the patient to dampen excessive pulmonary inflammation and promote tissue repair, with the goal of improving clinical outcomes in ARDS.
- Other names
- Living Related Donor Derived T Regulatory Cell TherapyRelated donor-derived T regulatory cellsHLA-matched or haploidentical allogeneic T regulatory cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on allogeneic T regulatory cells (Stanford University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic T regulatory cells (Stanford University).